## Patent Reference

- Title: Germ line locus variation pathogenicity prediction method, device, terminal and medium
- URL: https://patents.google.com/patent/CN115631791A/en

### Abstract

Abstract The application provides a method, a device, a terminal and a medium for predicting the variation pathogenicity of an embryonic system locus, a model training data set is obtained by assigning values to variation locus data and carrying out functional annotation, a CNN-XGboost model for predicting the variation pathogenicity of the embryonic system locus is obtained by training through using an optimized unique loss function, the classification effect of the model on the training set reaches 99% of accuracy, the accuracy in the prediction on a parallel non-intersection test data set reaches 96%, and the over-training bias of the existing method is overcome. The prediction model provided by the invention can assist in interpretation of gene mutation sites which are interpreted as having ambiguous meanings in clinical reports, improve accuracy of interpretation of the mutation sites and assist clinical decisions of doctors. In addition, the pathogenicity of the genetic variation site in the target region can be predicted through a model at the initial stage of product design, the design and optimization of the gene panel are assisted, and the missing detection of the pathogenic site is reduced, so that the product performance is improved.

### Description

Description Germ line locus variation pathogenicity prediction method, device, terminal and mediumTechnical Field The application relates to the technical field of molecular detection in the biological industry, in particular to a method, a device, a terminal and a medium for predicting the pathogenicity of germ line locus variation. Background The interpretation of genetic variation has important guiding significance for clinical decision making, including medication guidance, treatment modes and the like. With the development of the second generation high-throughput sequencing technology, more and more genetic variation information is discovered, and the clinical interpretation of variation sites faces more and more challenges. Although International Agency for Research on Cancer (IARC), the American society for Genetics and Genomics (ACMG), and the Association for the Interpretation of allelic variants of Germline mutations (Evidence-based Network for the Interpretation of geographic variant antibodies, ENGGMA) etc. provide guidelines for the Interpretation of variant sites, gene variants are divided into five types: pathogenicity, possibly pathogenicity, unclear significance, possibly benign, and benign. However, these interpretations are based on the correlation between common sites of genes and specific diseases, which are the basis of a great deal of research, and more on the correlation between common sites and specific diseases, which are based on past findings. For rare genes and mutations, the conventional information is limited and cannot be read well due to the lack of systematic research. For the detection of the cancer suppressor gene and the DNA damage repair gene without hot spots, all exons are covered, so that harmful variation is captured as much as possible. Because of the large coverage area, the variation that leads to large numbers of detections is classified as ambiguous due to insufficient evidence support, and has limited guiding significance for clinical decision making. Therefore, how to more accurately interpret the variation locus and reduce the classification of the locus with unknown meaning is a technical problem in the whole gene variation locus interpretation field, and the invention mainly provides a brand-new solution to the challenge. At present, a random forest model is adopted to train rare neutral mishaped variation so as to achieve the purpose of classifying the variation in the ClinVar database into benign and malignant categories, but the expression effect is not good, and the accuracy is only 0.893. And the random forest model is adopted to classify the variation in the ClinVar database into benign and malignant categories, the accuracy reaches 0.99, and the problems of strong bias and over-training exist. There are also good and bad classifications of variation in the ClinVar database by training a logistic regression model, but this tool also faces the problem of training and predicting from the same database. Therefore, a new machine learning model is an important issue to be researched in the field in order to solve the over-training of data and improve the model paradigm, especially the interpretation of gene variation of a specific population. Disclosure of Invention In view of the above-mentioned shortcomings of the prior art, the present application aims to provide a method, an apparatus, a terminal and a medium for predicting the pathogenicity of germ line locus mutation, so as to solve the technical problem that the prior machine learning model does not perform well in the prediction of the pathogenicity of germ line locus mutation. To achieve the above and other related objects, a first aspect of the present application provides a method for predicting pathogenicity of an germline locus variation, comprising: obtaining a variation site data set, carrying out corresponding assignment on each variation site data in the variation site data set according to whether the variation site data are harmful sites, and carrying out functional annotation on each variation site data based on one or more gene variation indexes to obtain a training data set; inputting a training data set subjected to dimensionality reduction based on a convolutional neural network into an XGboost machine learning model, and performing model training by using a loss function based on sample balance adjustment parameters to obtain a CNN-XGboost model for predicting the pathogenicity of germline locus variation. In some embodiments of the first aspect of the present application, assigning respective values to each of the variant site data in the variant site data set according to whether it is a nuisance site comprises: assigning pathogenic variant site data and possible pathogenic variant site data in the variant site data set according to harmful sites, and assigning benign variant site data and possible benign variant site data in the variant site data set according to harmless sites. In some embodiments of the first aspect of the present application, functionally annotating the variant site data based on one or more genetic variant indicators comprises: and functionally annotating the data of each variation site based on the gene mutation frequency value and/or the variation harmfulness prediction value. In some embodiments of the first aspect of the present application, the loss function based on the sample balance adjustment parameter comprises: introducing a beta coefficient into a Binary-Logistic regression loss function to perform adaptive adjustment on the classification probability; the loss function after introducing the β coefficient is expressed as: wherein N represents the number of samples, y i Denotes the ith sample tag, p i Representing the probability of the ith sample being classified into the first class; beta is a sample balance adjustment parameter. In some embodiments of the first aspect of the present application, the method further includes performing iterative update calculation on the loss function after introducing the β coefficient by first-order partial derivative calculation and second-order partial derivative calculation, where the calculation method is as follows: first order partial derivative calculation: gradient = p i (β-βy i +y i )-y i ； And (3) second-order partial derivative calculation: hessian = (y) i +β-βy i )p i (1-p i )； Wherein, y i Denotes the ith sample tag, p i Representing the probability of the ith sample being classified into the first class; beta is a sample balance adjustment parameter. In some embodiments of the first aspect of the present application, the method further comprises: performing multi-round adjustment on model parameters of the CNN-XGboost model based on a grid search method; in each round of adjustment, the parameter values of the optimal result are reserved after the coarse target range traversal is carried out on a plurality of model parameters, then the fine target range is used for the next round of adjustment, and the adjustment process is repeated until the model result is not promoted. In some embodiments of the first aspect of the present application, the structure of the CNN-XGBoost model comprises a convolutional layer and a fully-connected layer; connecting the input data with one or more full connection layers after the input data is calculated by the convolution layer; the convolutional layers are represented as follows:wherein C represents a convolutional layer; l is used for the indicator layer; p and q are used as indexes of a current layer and a next layer; i, j denotes the row and column indices; σ denotes the activation method; x represents a datum; θ represents a convolution kernel; b represents a deviation; (u, v) represents the dimensionality of the convolution kernel; the full connection layer converts the characteristics of the data input into the full connection layer through an activation function and a normalization function and then uses the converted data as the input data of the classifier; wherein the activation function comprises a ReLU activation function and the normalization function comprises a Softmax function. To achieve the above and other related objects, a second aspect of the present application provides an apparatus for predicting pathogenicity of an embryonal site variation, comprising: a training data set generation module, configured to obtain a mutation site data set, perform corresponding assignment on each mutation site data in the mutation site data set according to whether the mutation site data is a harmful site, and perform functional annotation on each mutation site data based on one or more genetic mutation indexes to obtain a training data set; and the prediction model generation module is used for inputting the training data set into an XGboost machine learning model, and using a loss function based on sample balance adjustment parameters to obtain a CNN-XGboost model for predicting the variation pathogenicity of the embryonic locus after model training. To achieve the above and other related objects, a third aspect of the present application provides a computer-readable storage medium having a computer program stored thereon, where the computer program is executed by a processor to implement the method for predicting the pathogenicity of germline locus variation. To achieve the above and other related objects, a fourth aspect of the present application provides an electronic terminal comprising: a processor and a memory; the memory is used for storing a computer program, and the processor is used for executing the computer program stored by the memory so as to enable the terminal to execute the germline locus variation pathogenicity prediction method. As described above, the method, the apparatus, the terminal and the medium for predicting pathogenicity of germline locus variation according to the present application have the following advantages: the method obtains a model training data set by assigning the mutation site data and carrying out functional annotation, obtains a CNN-XGboost model for predicting the pathogenicity of the germ line site mutation by training through using the optimized unique loss function, achieves 99% of accuracy on the classification effect of the model on the training set, achieves 96% of accuracy in the prediction of a parallel non-intersection test data set, and overcomes the over-training bias of the existing method. The prediction model provided by the invention can assist in interpretation of gene mutation sites which are interpreted as having ambiguous meanings in clinical reports, improve accuracy of interpretation of the mutation sites and assist clinical decisions of doctors. In addition, the pathogenicity of the genetic variation site in the target region can be predicted through a model at the initial stage of product design, the design and optimization of the gene panel are assisted, and the missing detection of the pathogenic site is reduced, so that the product performance is improved. The XGboost model has the characteristic of preventing overfitting, and meanwhile, the invention also makes the setting (from two databases) that the training set and the testing set are completely separated, so the universality of the model can be proved better. Drawings Fig. 1 is a flowchart illustrating a method for predicting the pathogenicity of an germline locus variation according to an embodiment of the present application. Fig. 2A shows a model training ROC curve for validation based on mutation site data with benign and malignant markers in the ClinVar database in an embodiment of the present application. Fig. 2B shows a model training ROC curve validated against variant site data with benign and malignant markers in the clinviae database in an embodiment of the present application. Fig. 3 is a schematic structural diagram of a CNN-XGBoost model for predicting pathogenicity of germline locus variation in an embodiment of the present application. Fig. 4 is a schematic structural diagram of an electronic terminal according to an embodiment of the present application. Fig. 5 is a schematic structural diagram illustrating an apparatus for predicting the pathogenicity of an germline site variation according to an embodiment of the present application. Detailed Description The following description of the embodiments of the present application is provided by way of specific examples, and other advantages and effects of the present application will be readily apparent to those skilled in the art from the disclosure herein. The application is capable of other and different embodiments and its several details are capable of modifications and various changes in detail without departing from the spirit of the application. It is to be noted that the features in the following embodiments and examples may be combined with each other without conflict. As used herein, the singular forms 'a', 'an' and 'the' are intended to include the plural forms as well, unless the context indicates otherwise. It will be further understood that the terms 'comprises,' 'comprising,' 'includes' and/or 'including' specify the presence of stated features, operations, elements, components, items, species, and/or groups, but do not preclude the presence, or addition of one or more other features, operations, elements, components, items, species, and/or groups thereof. The terms 'or' and/or 'as used herein are to be construed as inclusive or meaning any one or any combination. Thus, 'a, B or C' or 'a, B and/or C' means 'any of the following: a; b; c; a and B; a and C; b and C; A. b and C '. An exception to this definition will occur only when a combination of elements, functions or operations are inherently mutually exclusive in some way. In order to solve the problems in the background art, the invention provides a method, a device, a terminal and a medium for predicting the pathogenicity of germ line locus variation, and aims to improve the performance of a model on different data samples by combining innovation in two directions of XGboost machine learning by combining a deep convolutional neural network and an optimized loss function. Meanwhile, in order to make the objects, technical solutions and advantages of the present invention more clearly apparent, the technical solutions in the embodiments of the present invention are further described in detail by the following embodiments in conjunction with the accompanying drawings. It should be understood that the specific embodiments described herein are merely illustrative of the invention and are not intended to limit the invention. The embodiment of the invention provides a method for predicting the pathogenicity of germ line locus variation, a system for predicting the pathogenicity of germ line locus variation and a storage medium for storing an executable program for realizing the method for predicting the pathogenicity of germ line locus variation. For the implementation of the method for predicting the pathogenicity of germline site variation, the embodiments of the present invention will illustrate an exemplary scenario for predicting the pathogenicity of germline site variation. FIG. 1 shows a schematic flow chart of a method for predicting the pathogenicity of an embryonal site variation according to an embodiment of the present invention. The method for predicting the pathogenicity of the germline locus variation mainly comprises the following steps of: step S11: obtaining a variation site data set, correspondingly assigning values to each variation site data in the variation site data set according to whether the variation site data are harmful sites, and carrying out functional annotation on each variation site data based on one or more gene variation indexes to obtain a training data set. In some examples of this embodiment, the mutation site dataset may be obtained from a public database, and the obtained mutation site dataset includes the following data types: pathogenic variant site data, likely pathogenic variant site data, benign variant site data, and likely benign variant site data. The public database can be a ClinVar database which is a human genome variation database related to diseases and integrates data information of a plurality of databases such as dbSNP, dbVar, pubmed, OMIM and the like in terms of genetic variation and clinical manifestations to form a standard and credible genetic variation-clinical related database. In some examples of this embodiment, the way of assigning values to the mutation site data in the mutation site data set according to whether the mutation site data are harmful sites includes: assigning the pathogenic variant site data and the possible pathogenic variant site data in the variant site data set according to harmful sites, and assigning the benign variant site data and the possible benign variant site data in the variant site data set according to harmless sites. For example, pathogenic variant site data and potentially pathogenic variant site data are assigned a value of 1, and benign variant site data and potentially benign variant site data are assigned a value of 0, respectively. It should be understood that the above-mentioned assignment is only one embodiment of the present invention, and is not intended to limit the scope of the present invention. In some examples of this embodiment, the functionally annotating the variant site data based on one or more genetic variant indicators comprises: and functionally annotating the data of each variation site based on the gene mutation frequency value and/or the variation harmfulness prediction value. Alternatively, the gene mutation frequency values may be found from a large public database, such as the human gene variation database 1000 genes, exAC, ESP, gnomAD, etc. Alternatively, the predicted value of the hazard of the variation can be obtained using any one or more of the following predictive tools: SIFT (dirty interior From Tolerant) prediction tool, LRT (Likeliod Rate Test) prediction tool, mutation Association prediction tool, FATHMM (Functional Analysis Through high Markov Models) prediction tool, polyphen2 (polymorphic coding v 2) prediction tool, mutation Taster prediction tool, PROVEAN (Protein variance efficiency Analyzer) prediction tool, REVEL (random exterior variable Engine Generator) prediction tool, gene Splicer prediction tool, SPIDEX (a Pre-calculated Index of marketing variables) prediction tool, HSF (Human SpotFinder) prediction tool, GERP (Genomic Range route Generator) prediction tool, etc. The prediction of the harmfulness of the variation is performed by calculating corresponding scores by the prediction tool, for example, using any one of the following scores: mutPred score, eigen score, M-CAP score, FATHMM score, FATHMM-MKL coding score, GERP + + RS score, LRT score, metaLR score, metaSVM score, mutionissosser score, PROVEAN score, SIFT score, siPhy _29way \\ logOdds score, and the like. Step S12: inputting the training data set after dimensionality reduction into a CNN-XGboost machine learning model, and performing model training by using a loss function based on sample balance adjustment parameters to obtain the CNN-XGboost model for predicting the pathogenicity of germline locus variation. It should be understood that CNN-XGBoost is a machine learning model provided by the present invention and dedicated to predicting pathogenicity of germline locus variation, and mainly consists of a convolutional neural network CNN and an XGBoost model. The XGboost machine learning model is short for eXtreme Gradient Boosting and belongs to the field of Gradient lifting trees (GBDT), and the basic idea of the GBDT is to fit a new basic model to the residual error of the previous model, so that the deviation of an addition model is continuously reduced. The XGboost is a very important algorithm in ensemble learning, and the basic principle of the XGboost is to achieve the effect of overall improvement of a model by generating a series of weak learners and strengthening the performance of the weak learners in later training. XGBoost has many advantages over other models, particularly random forests: 1) Overfitting is prevented using multiple strategies including regularization, shrinkage, sampling, etc.; 2) Mathematically optimizing a loss function; 3) Parallelization is supported, and the training speed is high; 4) Processing of sparse data is added; 5) When the prediction result is converged, the tree building is stopped in advance, and the training speed is accelerated; 6) And the weight of the samples is set, some samples can be paid more attention by adjusting the weight, and the purpose of weak item reinforcement learning is achieved. In the CNN-XGBoost machine learning model of this embodiment, the convolutional neural network CNN is mainly composed of a convolutional layer and a full connection layer, and is used to reduce the input 18-dimensional original data to 6-dimensional data and input the data into the XGBoost model. The convolution layer consists of a plurality of convolution units, and the parameter of each convolution unit is obtained by optimization through a back propagation algorithm; the convolution operation is intended to extract different features of the input, for example, what the convolution layer of the first layer extracts is some low-level features, such as the edge, line and corner levels, and more layers of convolution layers can iteratively extract more complex features from the low-level features. The convolutional layer in this embodiment can be described as: wherein C represents a convolutional layer; l is used for the indicator layer; p and q are used as indexes of a current layer and a next layer; i, j denotes the row and column indices; σ denotes the activation method; x represents a datum; θ represents the convolution kernel. After passing through the convolutional layer, usually 1 or more than 1 fully-connected layer is connected, each neuron in the fully-connected layer is fully connected with all neurons in the previous layer, and the fully-connected layer can integrate local information with category distinction in the convolutional layer. In the embodiment, the full connection layer converts data input to the full connection layer into data with brand new characteristics through an activation function and a normalization function, and then the data is used as input of the XGboost machine learning model classifier. Specifically, the activation function may be selected from the list consisting of ReLU activation function: reLU (x) = max (0, x); the normalization function can be selected from a Softmax function: the XGboost machine learning model generally adopts Binary-Logistic regression loss function as an objective function in solving the two-classification problem, and performs optimal solution calculation on the following loss functions: wherein N represents the number of samples, y i Denotes the ith sample tag, p i Indicating the probability that the ith sample is classified into the first class. It should be understood that Binary-Logistic regression loss function refers to a two-class Logistic regression loss function, and the dependent variable y has only two values of yes and no, which are marked as 1 and 0. Assuming that the probability of y taking 'yes' is p under the action of the independent variables x1, x 2.,. Xp, the probability of taking 'no' is (1-p), which is the relationship between the probability p of y taking 'yes' occurrence and the independent variables x1, x 2.,. Xp. In particular, the process of optimal solution calculation is essentially an optimization process, and the main goal of the optimization is to find a direction towards which the parameters move to enable the value of the loss function to be reduced, so that the first order partial derivatives (gradients) and the second order partial derivatives (Hessian matrices) of the equations need to be calculated to update the loss function iteratively. First order partial derivatives (gradients): gradient = p i -y i (ii) a Formula 3) Second order partial derivative (hessian): hessian = p i (1-p i ) (ii) a Formula 4) Preferably, in order to be able to specifically adjust false negative and false positive, and to cope with the imbalance between the number of negative samples and the number of positive samples in a sample, in the embodiment of the present invention, the classification probability of the loss function is adaptively adjusted by introducing a β coefficient, which is specifically implemented as follows based on the loss function of the sample balance adjustment parameter: wherein N represents the number of samples, y i Denotes the ith sample tag, p i Representing the probability of the ith sample being classified into the first class; beta is a sample balance adjustment parameter. And the updating process of the adjusted target function carries out iterative updating through the adjusted first-order partial derivative and second-order partial derivative: first order partial derivatives (gradients): gradient = p i (β-βy i +y i )-y i (ii) a Formula 6) Second order partial derivative (hessian): sesian = (y) i +β-βy i )p i (1-p i ) (ii) a Formula 7) Wherein, y i Represents the ith sampleThe present label, p i Representing the probability of the ith sample being classified into the first class; beta is a sample balance adjustment parameter. Through iteration of the loss function based on the sample balance adjustment parameter, the classification probability of the loss function is correspondingly adjusted by introducing the beta coefficient, so that the imbalance of the number of negative samples and the number of positive samples in the samples can be well dealt with, and the purpose of optimizing the classification accuracy can be achieved. Further, in the embodiment of the present invention, besides using the personalized loss function based on the sample balance adjustment parameter, the model parameter of the XGBoost machine learning model is also optimized correspondingly, and the specific optimization process includes: performing multi-round adjustment on model parameters of the CNN-XGboost model for predicting the pathogenicity of the germline locus variation based on a grid search method; in each round of adjustment, the parameter values of the optimal result are reserved after the coarse target range traversal is carried out on a plurality of model parameters, then the fine target range is used for the next round of adjustment, and the adjustment process is repeated until the model result is not promoted. It should be understood that the grid search method is an exhaustive search method for specifying parameter values, and the optimal learning algorithm is obtained by optimizing the parameters of the estimation function through a cross-validation method. That is, possible values of each parameter are arranged and combined, all possible combination results are listed to generate a 'grid', then each combination is used for model training, cross validation is used for evaluating performance, and after all parameter combinations are tried by a fitting function, a proper classifier is returned to automatically adjust to the optimal parameter combination. It should be noted that the model parameters of the XGBoost machine learning model include, but are not limited to: maximum depth of tree (max _ depth), regularization term coefficients (gamma, alpha, lambda), minimum leaf node weight sum (min _ child _ weight), random sampling proportion (subsample), learning rate (eta), and so on. The maximum depth (max _ depth) of the tree is a number between 3 and 10, and the greater the value of the maximum depth (max _ depth) of the tree is, the more concrete the model learning is; the regularization term coefficient gamma represents the complexity of the regularization term for controlling the quantity of leaf nodes, a minimum loss function reduction value required by node splitting is formulated, and the algorithm is more conservative when the gamma value is larger; the regularization term coefficient alpha represents an L1 regularization term weight coefficient, and can be applied to the condition of high dimensionality to accelerate the algorithm speed; the regularization term coefficient lambda represents an L2 regularization term weight coefficient and is used for controlling the regularization part of the XGboost, so that overfitting can be reduced; the minimum leaf node weight sum (min _ child _ weight) determines the minimum leaf node sample weight sum, and a larger value is adopted to avoid the model from learning a local special sample; the random sampling proportion (subsample) is used to control the proportion of random sampling per tree, with smaller values leading to more conservative algorithms to avoid overfitting. The learning rate (eta) is used to improve the robustness of the model by reducing the weight of each step. For example, a first round of adjustment may be made for the maximum depth (max _ depth) of the tree, and the minimum leaf node weight sum (min _ child _ weight), e.g., the optimal result is obtained when the maximum depth is 9 and the minimum weight is 1. Adjusting the gamma value of the regular term coefficient by the second round of adjustment, and obtaining the optimal result when the gamma = 0; the second round also adjusts the training sample sampling proportion and the construction tree sampling proportion, and the optimal result is obtained when the two parameters are both 0.8. The third round adjusts for reg _ lambda (L2 regularization term weight coefficients), the optimal result is obtained when reg _ lambda = 0. And the fourth round adjusts the number of weak learners and the cross validation number, and the most result is obtained when the weak learners take 5000 values and the cross validation number takes 10 values. In order to verify the prediction accuracy of the improved CNN-XGboost model for predicting the pathogenicity of the germ line locus variation, the verification prediction classification is carried out by using 8849 variation locus data with good and malignant marks in a ClinVar database and a ClinVitae database, and the accuracy rate is up to 96%. Fig. 2A shows the result of a model training ROC curve for verifying the data of the variable sites with the benign and malignant markers in the ClinVar database, and fig. 2B shows the result of a model training ROC curve for verifying the data of the variable sites with the benign and malignant markers in the clinvitee database. It should be understood that ROC Curve (Receiver Operating Characteristic Curve) refers to a Receiver Operating Characteristic Curve for reflecting the relationship between sensitivity and specificity, the horizontal axis is specificity (also called False Positive Rate), and the closer the horizontal axis is to 0, the higher the accuracy is; the sensitivity (also called True Positive Rate) is shown on the ordinate, and a larger ordinate represents better accuracy. According to the Curve position, the whole graph can be divided into 2 parts, the area of the part below the Curve is called AUC (area Under Current) and used for representing prediction accuracy, and the higher the AUC value is, namely the larger the area Under the Curve is, the higher the prediction accuracy is; and the closer the curve is to the upper left corner, the higher the prediction accuracy. In addition, the embodiment of the invention also transversely compares the CNN-XGboost model for predicting the germ line locus variation pathogenicity, which is improved based on XGboost, with other prediction models, the test data are mainly from a ClinVar database and a ClinVitae database, the compared index is an AUC value (the area enclosed by the lower part of an ROC curve and a coordinate axis), and the prediction models participating in comparison comprise: the comparison results of the REVEL prediction model, the MetaLR prediction model, the MetaSVM prediction model, the CADD prediction model, the RENOV prediction model and the MLVar prediction model are as follows: the prediction model CNN-XGboost, the ACU value is 0.999, and the data source is ClinVar database/ClinVitae database; the prediction model REVEL, ACU value 0.957, data source is ClinVar database; the prediction model MetaLR, ACU value 0.917, the data source is ClinVar database; the prediction model MetaSVM has the ACU value of 0.933, and the data source is a ClinVar database; the prediction model CADD has an ACU value of 0.902, and the data source is a ClinVar database; the prediction model RENOVO, ACU value 0.994, data source is ClinVar database; the prediction model MLVar, ACU value 0.973, data source is clinvitee database. From the above, compared with the existing prediction model, the CNN-XGBoost model (CNN-XGBoost) for predicting the pathogenicity of germline locus variation, which is provided by the embodiment of the present invention and is improved based on XGBoost, is the best in AUC value. In this embodiment, the method for predicting the pathogenicity of germline locus variation further comprises: and predicting the ambiguous variant sites in the public database by using the trained CNN-XGboost model for predicting the pathogenicity of the germline locus variation so as to reduce the proportion of the ambiguous variant sites in the public database. Taking the ClinVar database as an example, the CNN-XGboost model for predicting the pathogenicity of the germline locus variation of the embodiment is adopted to predict 184920 variable loci with unknown meanings in the ClinVar database, wherein 24% of the variable loci are successfully predicted as harmful variations, so that the proportion of the variable loci with unknown meanings is greatly reduced, and the ClinVar database is more favorable for clinical decision guidance. In this embodiment, the method for predicting the pathogenicity of germline site variation further comprises: and (3) carrying out pathogenic variation prediction on the BRCA1 and BRCA2 gene coding regions by using a trained CNN-XGboost model for predicting the pathogenicity of germline locus variation so as to predict and identify harmful variation sites therein and then generate a malignant variation data set. It is understood that BRCA1 and BRCA2 are two genes having the function of inhibiting malignant tumor, and they can be used for coding and producing tumor suppressor protein, so that they have important functions in regulating human body cell replication, repairing genetic material DNA damage and normal cell growth. When either of these two genes is mutated or altered, the protein product is not or not functioning properly and DNA damage may not be repaired properly, thus the cells may develop alterations in other genetic information, resulting in cancer. That is, a positive BRCA1/2 gene means that the woman/man has a mutation in either the BRCA1 or BRCA2 gene, or both, and the woman/man is at increased risk for breast and/or ovarian cancer (none of the men). For example, 1762 effective variants generated after pathogenic variant prediction is performed on the coding regions of the BRCA1 and BRCA2 genes by using the CNN-XGBoost model for germ line locus variant pathogenicity prediction of the embodiment can be successfully annotated as harmful variant sites, thereby providing a great guiding significance for the development performance optimization of the Gene package (Gene Panel). Gene denotes a Gene, chr denotes a chromosome, start denotes a Start site on the chromosome, end denotes an End site on the chromosome, ref denotes a base at that site on the reference genome, and Alt denotes a base at which a mutation occurs as compared with the reference genome sequence. Wherein, 1762 effective variants can be successfully annotated as the information of the harmful variant sites as follows, each row represents the information of 2 harmful variant sites, and the information of each harmful variant site is represented as follows: gene (Gene), chromosome (Chr), start site (Start) on chromosome, end site (End) on chromosome, base (Ref) at that site on the reference genome, and base (Alt) at which mutations occur in reference genome sequence comparisons, i.e., gene, chr, start, end, ref, alt. BRCA1，17，41196332，41196332，T，A； BRCA1，17，41196368，41196368，C，T； BRCA1，17，41196409，41196409，G，A； BRCA1，17，41197230，41197230，C，T； BRCA1，17，41197404，41197404，G，A； BRCA1，17，41197709，41197709，G，T； BRCA1，17，41197710，41197710，G，A； BRCA1，17，41197724，41197724，T，C； BRCA1，17，41197729，41197729，T，C； BRCA1，17，41197732，41197732，G，A； BRCA1，17，41197733，41197733，T，C； BRCA1，17，41197738，41197738，A，G； BRCA1，17，41197741，41197741，T，C； BRCA1，17，41197742，41197742，C，A； BRCA1，17，41197747，41197747，C，T； BRCA1，17，41197753，41197753，T，C； BRCA1，17，41197756，41197756，A，T； BRCA1，17，41197757，41197757，G，C； BRCA1，17，41197771，41197771，A，G； BRCA1，17，41197783，41197783，C，T； BRCA1，17，41197784，41197784，G，T； BRCA1，17，41197790，41197790，C，T； BRCA1，17，41197791，41197791，C，T； BRCA1，17，41197798，41197798，G，A； BRCA1，17，41197802，41197802，C，T； BRCA1，17，41197814，41197814，C，T； BRCA1，17，41198270，41198270，G，A； BRCA1，17，41199651，41199651，G，A； BRCA1，17，41199656，41199656，T，C； BRCA1，17，41199663，41199663，G，C； BRCA1，17，41199669，41199669，C，A； BRCA1，17，41199670，41199670，A，T； BRCA1，17，41199683，41199683，C，A； BRCA1，17，41199690，41199690，C，G； BRCA1，17，41199692，41199692，G，A； BRCA1，17，41199695，41199695，T，C； BRCA1，17，41199698，41199698，A，G； BRCA1，17，41199703，41199703，C，G； BRCA1，17，41199707，41199707，A，G； BRCA1，17，41199716，41199716，A，G； BRCA1，17，41201070，41201070，A，G； BRCA1，17，41201085，41201085，T，A； BRCA1，17，41201092，41201092，A，G； BRCA1，17，41201130，41201130，A，G； BRCA1，17，41201133，41201133，C，T； BRCA1，17，41201141，41201141，G，T； BRCA1，17，41201142，41201142，C，T； BRCA1，17，41201146，41201146，G，A； BRCA1，17，41201148，41201148，G，A； BRCA1，17，41201150，41201150，G，T； BRCA1，17，41201151，41201151，A，T； BRCA1，17，41201153，41201153，T，C； BRCA1，17，41201155，41201155，A，C； BRCA1，17，41201201，41201201，T，C； BRCA1，17，41201210，41201210，A，G； BRCA1，17，41201287，41201287，C，T； BRCA1，17，41201341，41201341，A，G； BRCA1，17，41201390，41201390，G，T； BRCA1，17，41201442，41201442，A，G； BRCA1，17，41201460，41201460，T，C； BRCA1，17，41201462，41201462，A，G； BRCA1，17，41201476，41201476，A，G； BRCA1，17，41201482，41201482，A，G； BRCA1，17，41201611，41201611，C，T； BRCA1，17，41201612，41201612，G，A； BRCA1，17，41201658，41201658，G，A； BRCA1，17，41201682，41201682，T，C； BRCA1，17，41202579，41202579，G，A； BRCA1，17，41202688，41202688，G，A； BRCA1，17，41203060，41203060，G，T； BRCA1，17，41203069，41203069，C，T； BRCA1，17，41203078，41203078，A，T； BRCA1，17，41203079，41203079，C，G； BRCA1，17，41203081，41203081，T，G； BRCA1，17，41203085，41203085，G，C； BRCA1，17，41203087，41203087，C，T； BRCA1，17，41203099，41203099，G，A； BRCA1，17，41203103，41203103，C，T； BRCA1，17，41203112，41203112，C，T； BRCA1，17，41203115，41203115，A，C； BRCA1，17，41203118，41203118，T，A； BRCA1，17，41203123，41203123，C，T； BRCA1，17，41203128，41203128，T，A； BRCA1，17，41203132，41203132，G，A； BRCA1，17，41203134，41203134，T，C； BRCA1，17，41203140，41203140，A，G； BRCA1，17，41203676，41203676，C，T； BRCA1，17，41203707，41203707，G，A； BRCA1，17，41204361，41204361，G，A； BRCA1，17，41204653，41204653，T，C； BRCA1，17，41204856，41204856，G，A； BRCA1，17，41205941，41205941，A，G； BRCA1，17，41206097，41206097，C，T； BRCA1，17，41206852，41206852，T，C； BRCA1，17，41207660，41207660，C，T； BRCA1，17，41208216，41208216，A，C； BRCA1，17，41208971，41208971，A，G； BRCA1，17，41208991，41208991，C，T； BRCA1，17，41208992，41208992，G，A； BRCA1，17，41209049，41209049，C，T； BRCA1，17，41209071，41209071，T，G； BRCA1，17，41209074，41209074，T，C； BRCA1，17，41209076，41209076，T，C； BRCA1，17，41209081，41209081，G，C； BRCA1，17，41209084，41209084，T，A； BRCA1，17，41209085，41209085，T，C； BRCA1，17，41209087，41209087，T，A； BRCA1，17，41209091，41209091，G，A； BRCA1，17，41209094，41209094，C，T； BRCA1，17，41209095，41209095，G，A； BRCA1，17，41209096，41209096，C，T； BRCA1，17，41209097，41209097，T，C； BRCA1，17，41209098，41209098，T，C； BRCA1，17，41209106，41209106，T，G； BRCA1，17，41209110，41209110，G，T； BRCA1，17，41209111，41209111，G，A； BRCA1，17，41209115，41209115，C，T； BRCA1，17，41209118，41209118，C，A； BRCA1，17，41209123，41209123，G，A； BRCA1，17，41209125，41209125，C，A； BRCA1，17，41209133，41209133，C，T； BRCA1，17，41209138，41209138，G，A； BRCA1，17，41209142，41209142，T，G； BRCA1，17，41209148，41209148，T，C； BRCA1，17，41209151，41209151，T，C； BRCA1，17，41209162，41209162，A，G； BRCA1，17，41209575，41209575，G，A； BRCA1，17，41209618，41209618，C，T； BRCA1，17，41209627，41209627，C，A； BRCA1，17，41210602，41210602，T，C； BRCA1，17，41211653，41211653，A，G； BRCA1，17，41212180，41212180，C，T； BRCA1，17，41212547，41212547，C，T； BRCA1，17，41212805，41212805，C，T； BRCA1，17，41213013，41213013，C，T； BRCA1，17，41213318，41213318，C，T； BRCA1，17，41213760，41213760，C，T； BRCA1，17，41213893，41213893，C，T； BRCA1，17，41215331，41215331，T，C； BRCA1，17，41215350，41215350，C，T； BRCA1，17，41215358，41215358，G，T； BRCA1，17，41215359，41215359，C，T； BRCA1，17，41215369，41215369，T，C； BRCA1，17，41215377，41215377，A，G； BRCA1，17，41215403，41215403，T，C； BRCA1，17，41215825，41215825，C，T； BRCA1，17，41215826，41215826，G，A； BRCA1，17，41215876，41215876，T，C； BRCA1，17，41215882，41215882，T，A； BRCA1，17，41215890，41215890，C，A； BRCA1，17，41215892，41215892，G，A； BRCA1，17，41215893，41215893，A，G； BRCA1，17，41215894，41215894，A，G； BRCA1，17，41215896，41215896，T，C； BRCA1，17，41215901，41215901，A，C； BRCA1，17，41215904，41215904，T，A； BRCA1，17，41215909，41215909，A，C； BRCA1，17，41215917，41215917，C，T； BRCA1，17，41215919，41215919，C，T； BRCA1，17，41215920，41215920，G，A； BRCA1，17，41215921，41215921，C，T； BRCA1，17，41215935，41215935，T，A； BRCA1，17，41215939，41215939，T，C； BRCA1，17，41215940，41215940，C，G； BRCA1，17，41215945，41215945，T，C； BRCA1，17，41215947，41215947，C，G； BRCA1，17，41215948，41215948，G，A； BRCA1，17，41215954，41215954，A，C； BRCA1，17，41215958，41215958，A，G； BRCA1，17，41215959，41215959，A，G； BRCA1，17，41215977，41215977，T，G； BRCA1，17，41217103，41217103，C，T； BRCA1，17，41217111，41217111，C，T； BRCA1，17，41217380，41217380，A，G； BRCA1，17，41217874，41217874，C，T； BRCA1，17，41218007，41218007，T，C； BRCA1，17，41218237，41218237，T，C； BRCA1，17，41218333，41218333，G，A； BRCA1，17，41218467，41218467，C，T； BRCA1，17，41218707，41218707，C，G； BRCA1，17，41218716，41218716，G，A； BRCA1，17，41219341，41219341，G，T； BRCA1，17，41219360，41219360，C，T； BRCA1，17，41219397，41219397，G，A； BRCA1，17，41219420，41219420，C，T； BRCA1，17，41219507，41219507，G，A； BRCA1，17，41219517，41219517，C，T； BRCA1，17，41219560，41219560，C，T； BRCA1，17，41219625，41219625，C，G； BRCA1，17，41219628，41219628，T，C； BRCA1，17，41219643，41219643，G，T； BRCA1，17，41219644，41219644，A，G； BRCA1，17，41219648，41219648，G，C； BRCA1，17，41219657，41219657，G，A； BRCA1，17，41219690，41219690，C，T； BRCA1，17，41219701，41219701，G，T； BRCA1，17，41219704，41219704，C，G； BRCA1，17，41219706，41219706，C，T； BRCA1，17，41258479，41258479，G，A； BRCA1，17，41258493，41258493，A，G； BRCA1，17，41258513，41258513，G，A； BRCA1，17，41258516，41258516，C，T； BRCA1，17，41258518，41258518，T，C； BRCA1，17，41258519，41258519，T，C； BRCA1，17，41258529，41258529，G，C； BRCA1，17，41258534，41258534，G，A； BRCA1，17，41258535，41258535，T，G； BRCA1，17，41258536，41258536，T，C； BRCA1，17，41258539，41258539，A，G； BRCA1，17，41258542，41258542，A，T； BRCA1，17，41258543，41258543，T，G； BRCA1，17，41258547，41258547，A，C； BRCA1，17，41258566，41258566，A，C； BRCA1，17，41258882，41258882，G，A； BRCA1，17，41258946，41258946，T，C； BRCA1，17，41259049，41259049，C，T； BRCA1，17，41259113，41259113，G，A； BRCA1，17，41259316，41259316，G，A； BRCA1，17，41261233，41261233，C，T； BRCA1，17，41262101，41262101，C，T； BRCA1，17，41262102，41262102，G，A； BRCA1，17，41262191，41262191，G，A； BRCA1，17，41263430，41263430，G，A； BRCA1，17，41263610，41263610，G，A； BRCA1，17，41263845，41263845，A，C； BRCA1，17，41264146，41264146，G，A； BRCA1，17，41264339，41264339，G，A； BRCA1，17，41264749，41264749，C，G； BRCA1，17，41264753，41264753，C，T； BRCA1，17，41265071，41265071，T，C； BRCA1，17，41265776，41265776，A，G； BRCA1，17，41266997，41266997，C，T； BRCA1，17，41267050，41267050，G，A； BRCA1，17，41267632，41267632，G，A； BRCA1，17，41267742，41267742，C，A； BRCA1，17，41267762，41267762，A，G； BRCA1，17，41267777，41267777，G，C； BRCA1，17，41267783，41267783，T，C； BRCA1，17，41267788，41267788，A，G； BRCA1，17，41267793，41267793，C，T； BRCA1，17，41267807，41267807，A，G； BRCA1，17，41268598，41268598，C，T； BRCA1，17，41268746，41268746，G，A； BRCA1，17，41269180，41269180，C，T； BRCA1，17，41269315，41269315，C，T； BRCA1，17，41270355，41270355，T，C； BRCA1，17，41270463，41270463，G，A； BRCA1，17，41271051，41271051，G，A； BRCA1，17，41271222，41271222，C，T； BRCA1，17，41271914，41271914，C，T； BRCA1，17，41272996，41272996，G，A； BRCA1，17，41273095，41273095，G，A； BRCA1，17，41273248，41273248，C，T； BRCA1，17，41274789，41274789，C，T； BRCA1，17，41275655，41275655，G，A； BRCA1，17，41276036，41276036，G，T； BRCA1，17，41276046，41276046，T，C； BRCA1，17，41276057，41276057，C，T； BRCA1，17，41276058，41276058，T，C； BRCA1，17，41276065，41276065，C，A； BRCA1，17，41276072，41276072，G，C； BRCA1，17，41276078，41276078，T，G； BRCA1，17，41276082，41276082，A，G； BRCA1，17，41276087，41276087，T，A； BRCA1，17，41276090，41276090，A，G； BRCA1，17，41276092，41276092，C，T； BRCA1，17，41276093，41276093，G，A； BRCA1，17，41276094，41276094，C，T； BRCA1，17，41276095，41276095，G，A； BRCA1，17，41276101，41276101，C，A； BRCA1，17，41276107，41276107，A，T； BRCA1，17，41276111，41276111，C，A； BRCA1，17，41276134，41276134，T，C； BRCA1，17，41276493，41276493，G，A； BRCA1，17，41276952，41276952，G，A； BRCA1，17，41277187，41277187，G，C； BRCA1，17，41277231，41277231，C，T； BRCA1，17，41277275，41277275，G，A； BRCA1，17，41277277，41277277，G，A； BRCA1，17，41277329，41277329，G，A； BRCA1，17，41277393，41277393，G，A； BRCA2，13，32889634，32889634，A，G； BRCA2，13，32889656，32889656，C，T； BRCA2，13，32889784，32889784，A，G； BRCA2，13，32889792，32889792，A，G； BRCA2，13，32889802，32889802，C，T； BRCA2，13，32889803，32889803，G，A； BRCA2，13，32890026，32890026，C，T； BRCA2，13，32890558，32890558，G，A； BRCA2，13，32890565，32890565，T，C； BRCA2，13，32890586，32890586，T，C； BRCA2，13，32890595，32890595，A，G； BRCA2，13，32890599，32890599，T，A； BRCA2，13，32890625，32890625，A，G； BRCA2，13，32890649，32890649，C，T； BRCA2，13，32890650，32890650，G，A； BRCA2，13，32890653，32890653，G，A； BRCA2，13，32890657，32890657，C，T； BRCA2，13，32890660，32890660，A，G； BRCA2，13，32890665，32890665，G，A； BRCA2，13，32890667，32890667，A，G； BRCA2，13，32890682，32890682，A，G； BRCA2，13，32890684，32890684，A，G； BRCA2，13，32890726，32890726，T，G； BRCA2，13，32892875，32892875，G，A； BRCA2，13，32892885，32892885，G，A； BRCA2，13，32893232，32893232，T，G； BRCA2，13，32893268，32893268，C，T； BRCA2，13，32893297，32893297，G，A； BRCA2，13，32893317，32893317，C，T； BRCA2，13，32893318，32893318，G，A； BRCA2，13，32893345，32893345，A，G； BRCA2，13，32893368，32893368，G，A； BRCA2，13，32893380，32893380，A，G； BRCA2，13，32893381，32893381，A，G； BRCA2，13，32893384，32893384，A，G； BRCA2，13，32893385，32893385，T，C； BRCA2，13，32893387，32893387，T，C； BRCA2，13，32893403，32893403，T，C； BRCA2，13，32893412，32893412，C，T； BRCA2，13，32893413，32893413，G，A； BRCA2，13，32893415，32893415，T，C； BRCA2，13，32893437，32893437，A，G； BRCA2，13，32893442，32893442，A，G； BRCA2，13，32893449，32893449，C，A； BRCA2，13，32893465，32893465，A，G； BRCA2，13，32893480，32893480，G，A； BRCA2，13，32893724，32893724，G，A； BRCA2，13，32894322，32894322，G，A； BRCA2，13，32894738，32894738，G，A； BRCA2，13，32894977，32894977，C，T； BRCA2，13，32896073，32896073，T，C； BRCA2，13，32896676，32896676，G，A； BRCA2，13，32897438，32897438，C，T； BRCA2，13，32897533，32897533，G，A； BRCA2，13，32899203，32899203，A，G； BRCA2，13，32899206，32899206，G，A； BRCA2，13，32899219，32899219，A，G； BRCA2，13，32899239，32899239，A，G； BRCA2，13，32899248，32899248，C，T； BRCA2，13，32899249，32899249，G，A； BRCA2，13，32899293，32899293，C，T； BRCA2，13，32899309，32899309，G，A； BRCA2，13，32899316，32899316，T，C； BRCA2，13，32899778，32899778，C，T； BRCA2，13，32899833，32899833，A，G； BRCA2，13，32899838，32899838，C，T； BRCA2，13，32899878，32899878，C，T； BRCA2，13，32899899，32899899，G，A； BRCA2，13，32900006，32900006，C，T； BRCA2，13，32900149，32900149，T，C； BRCA2，13，32900218，32900218，T，G； BRCA2，13，32900236，32900236，A，G； BRCA2，13，32900248，32900248，C，T； BRCA2，13，32900249，32900249，T，C； BRCA2，13，32900253，32900253，A，G； BRCA2，13，32900269，32900269，C，T； BRCA2，13，32900289，32900289，T，C； BRCA2，13，32900368，32900368，T，C； BRCA2，13，32900399，32900399，C，T； BRCA2，13，32900400，32900400，A，G； BRCA2，13，32900408，32900408，A，G； BRCA2，13，32900409，32900409，A，G； BRCA2，13，32900419，32900419，G，A； BRCA2，13，32900471，32900471，A，G； BRCA2，13，32900547，32900547，G，A； BRCA2，13，32900619，32900619，A，G； BRCA2，13，32900620，32900620，T，C； BRCA2，13，32900633，32900633，C，T； BRCA2，13，32900634，32900634，A，G； BRCA2，13，32900637，32900637，G，T； BRCA2，13，32900639，32900639，C，T； BRCA2，13，32900640，32900640，G，A； BRCA2，13，32900645，32900645，A，G； BRCA2，13，32900664，32900664，A，G； BRCA2，13，32900675，32900675，G，A； BRCA2，13，32900697，32900697，C，T； BRCA2，13，32900725，32900725，C，T； BRCA2，13，32900728，32900728，C，T； BRCA2，13，32900752，32900752，T，C； BRCA2，13，32900756，32900756，A，C； BRCA2，13，32900763，32900763，A，G； BRCA2，13，32901291，32901291，T，C； BRCA2，13，32901731，32901731，C，T； BRCA2，13，32902381，32902381，C，T； BRCA2，13，32903579，32903579，G，T； BRCA2，13，32903580，32903580，T，C； BRCA2，13，32903581，32903581，C，T； BRCA2，13，32903600，32903600，G，T； BRCA2，13，32903622，32903622，C，T； BRCA2，13，32903636，32903636，A，G； BRCA2，13，32903838，32903838，C，T； BRCA2，13，32904497，32904497，G，A； BRCA2，13，32904740，32904740，G，A； BRCA2，13，32905043，32905043，A，T； BRCA2，13，32905059，32905059，G，A； BRCA1，17，41219707，41219707，G，A； BRCA1，17，41219708，41219708，A，G； BRCA1，17，41219710，41219710，C，G； BRCA1，17，41219780，41219780，T，C； BRCA1，17，41219804，41219804，T，C； BRCA1，17，41220288，41220288，C，T； BRCA1，17，41220797，41220797，T，C； BRCA1，17，41222099，41222099，C，T； BRCA1，17，41222945，41222945，A，G； BRCA1，17，41222958，41222958，G，A； BRCA1，17，41222966，41222966，A，G； BRCA1，17，41222968，41222968，A，C； BRCA1，17，41222969，41222969，C，T； BRCA1，17，41222993，41222993，G，T； BRCA1，17，41223003，41223003，G，A； BRCA1，17，41223004，41223004，T，C； BRCA1，17，41223008，41223008，A，G； BRCA1，17，41223016，41223016，A，C； BRCA1，17，41223020，41223020，T，A； BRCA1，17，41223023，41223023，C，G； BRCA1，17，41223032，41223032，G，C； BRCA1，17，41223034，41223034，T，C； BRCA1，17，41223051，41223051，G，A； BRCA1，17，41223052，41223052，C，G； BRCA1，17，41223059，41223059，C，G； BRCA1，17，41223062，41223062，A，G； BRCA1，17，41223065，41223065，A，G； BRCA1，17，41223072，41223072，G，C； BRCA1，17，41223076，41223076，T，A； BRCA1，17，41223081，41223081，G，A； BRCA1，17，41223082，41223082，C，T； BRCA1，17，41223083，41223083，A，G； BRCA1，17，41223094，41223094，T，C； BRCA1，17，41223102，41223102，G，T； BRCA1，17，41223103，41223103，A，T； BRCA1，17，41223112，41223112，C，G； BRCA1，17，41223114，41223114，T，C； BRCA1，17，41223115，41223115，T，G； BRCA1，17，41223116，41223116，C，T； BRCA1，17，41223122，41223122，G，A； BRCA1，17，41223128，41223128，T，A； BRCA1，17，41223142，41223142，T，G； BRCA1，17，41223148，41223148，A，G； BRCA1，17，41223149，41223149，T，C； BRCA1，17，41223154，41223154，T，C； BRCA1，17，41223155，41223155，G，A； BRCA1，17，41223158，41223158，G，C； BRCA1，17，41223165，41223165，C，T； BRCA1，17，41223166，41223166，G，A； BRCA1，17，41223169，41223169，C，T； BRCA1，17，41223185，41223185，G，A； BRCA1，17，41223187，41223187，C，T； BRCA1，17，41223191，41223191，A，G； BRCA1，17，41223195，41223195，G，T； BRCA1，17，41223197，41223197，A，G； BRCA1，17，41223208，41223208，G，A； BRCA1，17，41223210，41223210，T，G； BRCA1，17，41223215，41223215，A，C； BRCA1，17，41223216，41223216，G，A； BRCA1，17，41223224，41223224，G，A； BRCA1，17，41223228，41223228，A，G； BRCA1，17，41223235，41223235，A，G； BRCA1，17，41223242，41223242，G，C； BRCA1，17，41223243，41223243，T，C； BRCA1，17，41223246，41223246，G，T； BRCA1，17，41223247，41223247，G，C； BRCA1，17，41223249，41223249，G，A； BRCA1，17，41223255，41223255，T，G； BRCA1，17，41223256，41223256，C，T； BRCA1，17，41223742，41223742，C，T； BRCA1，17，41224266，41224266，C，T； BRCA1，17，41224280，41224280，C，T； BRCA1，17，41225529，41225529，C，T； BRCA1，17，41226317，41226317，G，C； BRCA1，17，41226352，41226352，A，G； BRCA1，17，41226356，41226356，T，A； BRCA1，17，41226359，41226359，C，T； BRCA1，17，41226365，41226365，A，G； BRCA1，17，41226367，41226367，G，A； BRCA1，17，41226379，41226379，C，T； BRCA1，17，41226380，41226380，G，A； BRCA1，17，41226384，41226384，A，C； BRCA1，17，41226387，41226387，C，T； BRCA1，17，41226388，41226388，G，A； BRCA1，17，41226389，41226389，T，A； BRCA1，17，41226394，41226394，C，T； BRCA1，17，41226395，41226395，C，T； BRCA1，17，41226404，41226404，T，A； BRCA1，17，41226409，41226409，C，T； BRCA1，17，41226422，41226422，A，T； BRCA1，17，41226429，41226429，C，A； BRCA1，17，41226431，41226431，A，G； BRCA1，17，41226432，41226432，C，T； BRCA1，17，41226441，41226441，G，A； BRCA1，17，41226443，41226443，T，C； BRCA1，17，41226445，41226445，C，A； BRCA1，17，41226451，41226451，A，G； BRCA1，17，41226464，41226464，C，A； BRCA1，17，41226475，41226475，A，G； BRCA1，17，41226480，41226480，C，G； BRCA1，17，41226483，41226483，A，G； BRCA1，17，41226484，41226484，G，A； BRCA1，17，41226492，41226492，G，A； BRCA1，17，41226516，41226516，A，C； BRCA1，17，41226526，41226526，A，G； BRCA1，17，41226535，41226535，T，C； BRCA1，17，41226548，41226548，T，C； BRCA1，17，41226549，41226549，A，T； BRCA1，17，41226601，41226601，G，C； BRCA1，17，41228042，41228042，G，A； BRCA1，17，41228495，41228495，T，C； BRCA1，17，41228504，41228504，C，T； BRCA1，17，41228508，41228508，T，C； BRCA1，17，41228509，41228509，C，T； BRCA1，17，41228511，41228511，A，T； BRCA1，17，41228513，41228513，T，C； BRCA1，17，41228517，41228517，G，A； BRCA1，17，41228518，41228518，G，T； BRCA1，17，41228523，41228523，T，A； BRCA1，17，41228533，41228533，T，G； BRCA1，17，41228536，41228536，T，C； BRCA1，17，41228556，41228556，T，G； BRCA1，17，41228558，41228558，A，G； BRCA1，17，41228572，41228572，A，G； BRCA1，17，41228579，41228579，T，C； BRCA1，17，41228586，41228586，T，C； BRCA1，17，41228588，41228588，C，T； BRCA1，17，41228591，41228591，G，A； BRCA1，17，41228593，41228593，T，C； BRCA1，17，41228607，41228607，C，A； BRCA1，17，41228618，41228618，T，A； BRCA1，17，41228620，41228620，A，C； BRCA1，17，41228623，41228623，T，G； BRCA1，17，41228676，41228676，T，C； BRCA1，17，41230044，41230044，G，A； BRCA1，17，41230955，41230955，G，A； BRCA1，17，41230982，41230982，C，T； BRCA1，17，41231086，41231086，G，A； BRCA1，17，41231516，41231516，C，T； BRCA1，17，41232108，41232108，A，C； BRCA1，17，41232698，41232698，C，T； BRCA1，17，41234405，41234405，G，T； BRCA1，17，41234422，41234422，T，A； BRCA1，17，41234425，41234425，T，C； BRCA1，17，41234429，41234429，G，T； BRCA1，17，41234433，41234433，T，A； BRCA1，17，41234435，41234435，C，A； BRCA1，17，41234437，41234437，T，C； BRCA1，17，41234439，41234439，G，A； BRCA1，17，41234442，41234442，C，T； BRCA1，17，41234447，41234447，T，C； BRCA1，17，41234449，41234449，T，C； BRCA1，17，41234450，41234450，C，T； BRCA1，17，41234451，41234451，G，A； BRCA1，17，41234456，41234456，T，C； BRCA1，17，41234457，41234457，C，T； BRCA1，17，41234461，41234461，A，G； BRCA1，17，41234463，41234463，G，C； BRCA1，17，41234467，41234467，A，C； BRCA1，17，41234473，41234473，G，A； BRCA1，17，41234479，41234479，T，C； BRCA1，17，41234480，41234480，A，G； BRCA1，17，41234487，41234487，A，C； BRCA1，17，41234492，41234492，T，C； BRCA1，17，41234494，41234494，G，A； BRCA1，17，41234496，41234496，T，C； BRCA1，17，41234497，41234497，G，T； BRCA1，17，41234504，41234504，G，A； BRCA1，17，41234511，41234511，T，C； BRCA1，17，41234517，41234517，G，A； BRCA1，17，41234518，41234518，C，A； BRCA1，17，41234521，41234521，T，A； BRCA1，17，41234522，41234522，T，C； BRCA1，17，41234524，41234524，T，C； BRCA1，17，41234542，41234542，A，G； BRCA1，17，41234545，41234545，C，T； BRCA1，17，41234552，41234552，T，C； BRCA1，17，41234553，41234553，G，C； BRCA1，17，41234554，41234554，C，A； BRCA1，17，41234555，41234555，T，C； BRCA1，17，41234577，41234577，G，A； BRCA1，17，41234582，41234582，G，T； BRCA1，17，41234584，41234584，A，C； BRCA1，17，41234602，41234602，C，T； BRCA1，17，41234603，41234603，G，A； BRCA1，17，41234611，41234611，G，C； BRCA1，17，41236043，41236043，G，A； BRCA1，17，41236779，41236779，G，A； BRCA1，17，41237074，41237074，A，G； BRCA1，17，41237869，41237869，A，G； BRCA1，17，41237953，41237953，G，A； BRCA1，17，41239928，41239928，T，C； BRCA1，17，41240750，41240750，G，A； BRCA1，17，41240915，41240915，A，G； BRCA1，17，41242931，41242931，C，T； BRCA1，17，41242932，41242932，G，A； BRCA1，17，41242949，41242949，C，T； BRCA1，17，41242951，41242951，C，T； BRCA1，17，41242952，41242952，G，A； BRCA1，17，41242961，41242961，C，T； BRCA1，17，41242964，41242964，A，T； BRCA1，17，41242968，41242968，G，A； BRCA1，17，41242970，41242970，T，A； BRCA1，17，41242983，41242983，T，C； BRCA1，17，41242984，41242984，G，A； BRCA1，17，41242988，41242988，G，C； BRCA1，17，41242990，41242990，A，G； BRCA1，17，41242991，41242991，T，A； BRCA1，17，41242993，41242993，G，A； BRCA1，17，41242994，41242994，C，T； BRCA1，17，41243002，41243002，A，T； BRCA1，17，41243004，41243004，T，G； BRCA1，17，41243007，41243007，T，G； BRCA1，17，41243008，41243008，C，A； BRCA1，17，41243011，41243011，A，G； BRCA1，17，41243014，41243014，C，G； BRCA1，17，41243015，41243015，G，A； BRCA1，17，41243016，41243016，C，T； BRCA1，17，41243030，41243030，A，G； BRCA1，17，41243031，41243031，C，T； BRCA1，17，41243034，41243034，C，T； BRCA1，17，41243039，41243039，T，G； BRCA1，17，41243040，41243040，G，A； BRCA1，17，41243049，41243049，C，G； BRCA1，17，41243064，41243064，A，G； BRCA1，17，41243069，41243069，G，A； BRCA1，17，41243409，41243409，C，T； BRCA1，17，41243422，41243422，G，A； BRCA2，13，32905069，32905069，A，G； BRCA2，13，32905076，32905076，C，T； BRCA2，13，32905079，32905079，T，C； BRCA2，13，32905084，32905084，A，G； BRCA2，13，32905105，32905105，A，G； BRCA2，13，32905106，32905106，T，C； BRCA2，13，32905107，32905107，A，T； BRCA2，13，32905115，32905115，C，T； BRCA2，13，32905116，32905116，G，A； BRCA2，13，32905118，32905118，T，A； BRCA2，13，32905128，32905128，G，A； BRCA2，13，32905144，32905144，A，C； BRCA2，13，32905148，32905148，A，G； BRCA2，13，32905155，32905155，G，A； BRCA2，13，32905168，32905168，G，A； BRCA2，13，32905185，32905185，T，C； BRCA2，13，32905265，32905265，G，A； BRCA2，13，32905272，32905272，C，T； BRCA2，13，32906389，32906389，T，C； BRCA2，13，32906399，32906399，A，G； BRCA2，13，32906426，32906426，G，A； BRCA2，13，32906434，32906434，A，G； BRCA2，13，32906437，32906437，T，A； BRCA2，13，32906446，32906446，T，G； BRCA2，13，32906484，32906484，T，G； BRCA2，13，32906500，32906500，A，G； BRCA2，13，32906508，32906508，C，T； BRCA2，13，32906521，32906521，C，T； BRCA2，13，32906525，32906525，G，A； BRCA2，13，32906541，32906541，C，A； BRCA2，13，32906576，32906576，C，T； BRCA2，13，32906627，32906627，G，A； BRCA2，13，32906630，32906630，G，A； BRCA2，13，32906641，32906641，A，G； BRCA2，13，32906655，32906655，A，G； BRCA2，13，32906666，32906666，A，G； BRCA2，13，32906671，32906671，C，T； BRCA2，13，32906674，32906674，A，G； BRCA2，13，32906707，32906707，T，C； BRCA2，13，32906719，32906719，A，G； BRCA2，13，32906722，32906722，T，C； BRCA2，13，32906742，32906742，T，C； BRCA2，13，32906751，32906751，G，A； BRCA2，13，32906768，32906768，A，C； BRCA2，13，32906774，32906774，G，A； BRCA2，13，32906775，32906775，T，C； BRCA2，13，32906781，32906781，C，T； BRCA2，13，32906782，32906782，G，A； BRCA2，13，32906806，32906806，A，G； BRCA2，13，32906817，32906817，C，A； BRCA2，13，32906818，32906818，A，G； BRCA2，13，32906826，32906826，A，T； BRCA2，13，32906850，32906850，C，T； BRCA2，13，32906854，32906854，A，G； BRCA2，13，32906874，32906874，A，G； BRCA2，13，32906888，32906888，G，A； BRCA2，13，32906896，32906896，C，A； BRCA2，13，32906908，32906908，A，G； BRCA2，13，32906940，32906940，C，T； BRCA2，13，32906951，32906951，T，C； BRCA2，13，32906958，32906958，G，A； BRCA2，13，32906962，32906962，T，G； BRCA2，13，32906983，32906983，G，C； BRCA2，13，32906985，32906985，A，G； BRCA2，13，32906989，32906989，A，G； BRCA2，13，32906991，32906991，T，C； BRCA2，13，32907002，32907002，A，G； BRCA2，13，32907018，32907018，G，A； BRCA2，13，32907019，32907019，A，G； BRCA2，13，32907059，32907059，C，T； BRCA2，13，32907069，32907069，A，G； BRCA2，13，32907077，32907077，A，G； BRCA2，13，32907119，32907119，A，G； BRCA2，13，32907125，32907125，T，C； BRCA2，13，32907132，32907132，T，C； BRCA2，13，32907154，32907154，A，G； BRCA2，13，32907157，32907157，G，A； BRCA2，13，32907159，32907159，C，T； BRCA2，13，32907166，32907166，T，C； BRCA2，13，32907175，32907175，T，C； BRCA2，13，32907183，32907183，A，G； BRCA2，13，32907190，32907190，T，C； BRCA2，13，32907198，32907198，A，G； BRCA2，13，32907209，32907209，G，A； BRCA2，13，32907215，32907215，G，A； BRCA2，13，32907228，32907228，G，A； BRCA2，13，32907232，32907232，A，G； BRCA2，13，32907235，32907235，G，A； BRCA2，13，32907260，32907260，A，G； BRCA2，13，32907296，32907296，G，C； BRCA2，13，32907331，32907331，A，G； BRCA2，13，32907334，32907334，T，C； BRCA2，13，32907345，32907345，C，T； BRCA2，13，32907371，32907371，A，G； BRCA2，13，32907379，32907379，T，G； BRCA2，13，32907394，32907394，T，C； BRCA2，13，32907401，32907401，G，A； BRCA2，13，32907413，32907413，T，C； BRCA2，13，32907415，32907415，T，A； BRCA2，13，32907432，32907432，C，T； BRCA2，13，32907433，32907433，G，A； BRCA2，13，32907453，32907453，T，G； BRCA2，13，32907467，32907467，G，C； BRCA2，13，32907470，32907470，C，T； BRCA2，13，32907500，32907500，C，T； BRCA2，13，32907523，32907523，A，G； BRCA2，13，32907526，32907526，T，A； BRCA2，13，32907529，32907529，C，T； BRCA2，13，32907540，32907540，T，C； BRCA2，13，32907767，32907767，C，T； BRCA2，13，32908347，32908347，C，T； BRCA2，13，32908724，32908724，T，C； BRCA2，13，32909615，32909615，G，C； BRCA2，13，32910385，32910385，T，G； BRCA2，13，32910403，32910403，T，C； BRCA2，13，32910430，32910430，C，T； BRCA2，13，32910431，32910431，T，C； BRCA2，13，32910452，32910452，G，T； BRCA2，13，32910457，32910457，A，G； BRCA2，13，32910458，32910458，A，G； BRCA2，13，32910508，32910508，A，C； BRCA2，13，32910512，32910512，G，A； BRCA2，13，32910516，32910516，C，G； BRCA2，13，32910517，32910517，A，G； BRCA2，13，32910518，32910518，T，C； BRCA2，13，32910522，32910522，C，T； BRCA2，13，32910538，32910538，C，T； BRCA2，13，32910564，32910564，C，A； BRCA2，13，32910590，32910590，T，A； BRCA2，13，32910613，32910613，T，C； BRCA2，13，32910625，32910625，C，A； BRCA2，13，32910629，32910629，C，T； BRCA2，13，32910637，32910637，A，G； BRCA2，13，32910644，32910644，G，A； BRCA2，13，32910663，32910663，A，G； BRCA2，13，32910665，32910665，A，G； BRCA2，13，32910673，32910673，A，G； BRCA2，13，32910723，32910723，C，T； BRCA2，13，32910744，32910744，C，G； BRCA2，13，32910748，32910748，C，T； BRCA2，13，32910750，32910750，T，C； BRCA2，13，32910757，32910757，C，T； BRCA2，13，32910761，32910761，A，G； BRCA2，13，32910768，32910768，T，C； BRCA2，13，32910778，32910778，T，C； BRCA2，13，32910795，32910795，C，T； BRCA2，13，32910798，32910798，T，G； BRCA2，13，32910816，32910816，C，T； BRCA2，13，32910820，32910820，G，A； BRCA2，13，32910822，32910822，A，G； BRCA2，13，32910840，32910840，T，C； BRCA2，13，32910851，32910851，A，G； BRCA2，13，32910854，32910854，G，A； BRCA2，13，32910867，32910867，A，G； BRCA2，13，32910886，32910886，C，T； BRCA2，13，32910905，32910905，T，C； BRCA2，13，32910943，32910943，G，A； BRCA2，13，32910949，32910949，A，G； BRCA2，13，32910959，32910959，G，A； BRCA2，13，32910966，32910966，A，G； BRCA2，13，32910967，32910967，T，G； BRCA2，13，32910972，32910972，A，G； BRCA2，13，32910982，32910982，C，T； BRCA2，13，32910983，32910983，G，A； BRCA2，13，32910991，32910991，G，A； BRCA2，13，32910999，32910999，C，T； BRCA2，13，32911007，32911007，T，C； BRCA2，13，32911036，32911036，G，C； BRCA2，13，32911042，32911042，A，G； BRCA2，13，32911082，32911082，C，T； BRCA2，13，32911083，32911083，A，T； BRCA2，13，32911095，32911095，C，T； BRCA2，13，32911098，32911098，C，T； BRCA2，13，32911134，32911134，A，G； BRCA2，13，32911150，32911150，T，C； BRCA2，13，32911151，32911151，G，A； BRCA2，13，32911170，32911170，A，G； BRCA2，13，32911172，32911172，G，A； BRCA2，13，32911175，32911175，G，A； BRCA2，13，32911192，32911192，T，C； BRCA2，13，32911220，32911220，C，T； BRCA2，13，32911246，32911246，C，T； BRCA2，13，32911247，32911247，G，A； BRCA2，13，32911264，32911264，C，T； BRCA2，13，32911271，32911271，A，G； BRCA2，13，32911279，32911279，A，G； BRCA2，13，32911284，32911284，G，A； BRCA2，13，32911292，32911292，G，A； BRCA2，13，32911297，32911297，T，A； BRCA2，13，32911299，32911299，A，G； BRCA2，13，32911308，32911308，C，G； BRCA2，13，32911345，32911345，T，G； BRCA2，13，32911376，32911376，C，T； BRCA2，13，32911378，32911378，T，C； BRCA2，13，32911390，32911390，T，C； BRCA2，13，32911410，32911410，C，T； BRCA2，13，32911411，32911411，G，A； BRCA2，13，32911416，32911416，T，C； BRCA2，13，32911428，32911428，T，C； BRCA2，13，32911447，32911447，A，G； BRCA2，13，32911457，32911457，T，G； BRCA2，13，32911522，32911522，A，G； BRCA2，13，32911524，32911524，C，T； BRCA2，13，32911543，32911543，C，T； BRCA2，13，32911562，32911562，A，G； BRCA2，13，32911588，32911588，A，G； BRCA2，13，32911604，32911604，T，C； BRCA2，13，32911611，32911611，C，T； BRCA2，13，32911643，32911643，T，C； BRCA2，13，32911644，32911644，T，C； BRCA2，13，32911651，32911651，A，G； BRCA2，13，32911658，32911658，C，T； BRCA2，13，32911672，32911672，C，A； BRCA2，13，32911677，32911677，C，G； BRCA2，13，32911680，32911680，A，T； BRCA2，13，32911696，32911696，A，G； BRCA2，13，32911703，32911703，C，T； BRCA2，13，32911704，32911704，A，G； BRCA2，13，32911710，32911710，A，G； BRCA2，13，32911711，32911711，G，A； BRCA2，13，32911718，32911718，G，A； BRCA2，13，32911733，32911733，T，C； BRCA2，13，32911757，32911757，C，T； BRCA2，13，32911801，32911801，A，G； BRCA2，13，32911811，32911811，C，T； BRCA2，13，32911838，32911838，A，G； BRCA2，13，32911843，32911843，A，G； BRCA2，13，32911860，32911860，G，C。 In order to better understand the structure of the CNN-XGBoost model for predicting the pathogenicity of germline locus variation in the embodiments of the present invention, the following description will be made with reference to fig. 3: first, assignment and functional Annotation (Annotation) are performed on mutation site datasets obtained from databases, such as ClinVar database and Clinvitae database, and the functional Annotation is mainly performed based on gene mutation frequency values and/or mutation hazard predictive values. The gene mutation frequency value can be found from a large public database, such as a human gene variation database 1000 genes, an ExAC, an ESP, a gnomaD and the like; the variant hazard prediction value can be obtained using any one or more of the following prediction tools, and the prediction score can include the following types: mutPRed score, eigen score, M-CAP score, FATHMM score, FATHMM-MKL coding score, GERP + + _ RS score, LRT score, metaLR score, metaSVM score, mutionissossossosser score, PROVEAN score, SIFT score, siPhy _29way _logOddsscore, and the like. And secondly, taking the generated data set as a training set of model training, inputting the training set into a convolutional layer for convolution calculation, inputting the convolution calculation result into a full-link layer, and finally inputting the convolution calculation result into a classifier of XGboost for classification prediction. The prediction results are in two categories, benign (benign) and pathogenic (pathogenic). Finally, model parameter optimization (superparameter tuning) is carried out in the training process, namely, model parameters of the CNN-XGboost model for predicting the pathogenicity of the germline locus variation are subjected to multi-round adjustment based on a grid search method; in each round of adjustment, the parameter values of the optimal result are reserved after the coarse target range traversal is carried out on a plurality of model parameters, then the fine target range is used for the next round of adjustment, and the adjustment process is repeated until the model result is not promoted. It should be noted that the germ line locus variation pathogenicity prediction method provided by the embodiment of the present invention may be implemented by a terminal side or a server side, and as for a hardware structure of the germ line locus variation pathogenicity prediction terminal, please refer to fig. 4, which is an optional hardware structure schematic diagram of the electronic terminal 400 provided by the embodiment of the present invention, and the terminal 400 may be a mobile phone, a computer device, a tablet device, a personal digital processing device, a factory background processing device, and the like. The electronic terminal 400 includes: at least one processor 401, memory 402, at least one network interface 404, and a user interface 406. The various components in the device are coupled together by a bus system 405. It will be appreciated that the bus system 405 is used to enable the communication of connections between these components. The bus system 405 includes a power bus, a control bus, and a status signal bus in addition to a data bus. But for the sake of clarity the various buses are labeled as bus systems in figure 4. The user interface 406 may include, among other things, a display, a keyboard, a mouse, a trackball, a click gun, keys, buttons, a touch pad, or a touch screen. It will be appreciated that the memory 402 can be either volatile memory or nonvolatile memory, and can include both volatile and nonvolatile memory. Among them, the nonvolatile Memory may be a Read Only Memory (ROM), a Programmable Read-Only Memory (PROM), which serves as an external cache. By way of example, and not limitation, many forms of RAM are available, such as Static Random Access Memory (SRAM), synchronous Static Random Access Memory (SSRAM). The described memory for embodiments of the present invention is intended to comprise, without being limited to, these and any other suitable types of memory. The memory 402 in the embodiments of the present invention is used to store various kinds of data to support the operation of the electronic terminal 400. Examples of such data include: any executable programs for operating on the electronic terminal 400, such as an operating system 4021 and application programs 4022; the operating system 4021 includes various system programs such as a framework layer, a core library layer, a driver layer, and the like, for implementing various basic services and processing hardware-based tasks. The application 4022 may include various applications such as a media player (MediaPlayer), a Browser (Browser), and the like, for implementing various application services. The method for predicting pathogenicity of germline site variation provided by the embodiment of the invention can be included in the application 4022. The method disclosed by the embodiment of the invention can be applied to the processor 401, or implemented by the processor 401. The processor 401 may be an integrated circuit chip having signal processing capabilities. In implementation, the steps of the above method may be performed by integrated logic circuits of hardware or instructions in the form of software in the processor 401. The Processor 401 described above may be a general purpose Processor, a Digital Signal Processor (DSP), or other programmable logic device, discrete gate or transistor logic device, discrete hardware components, or the like. Processor 401 may implement or perform the methods, steps, and logic blocks disclosed in embodiments of the present invention. The general purpose processor 401 may be a microprocessor or any conventional processor or the like. The steps of the method provided by the embodiment of the present invention may be directly implemented by a hardware decoding processor, or implemented by a combination of hardware and software modules in the decoding processor. The software modules may be located in a storage medium having a memory and a processor reading the information in the memory and combining the hardware to perform the steps of the method. In an exemplary embodiment, the electronic terminal 400 may be used by one or more Application Specific Integrated Circuits (ASICs), DSPs, programmable Logic Devices (PLDs), complex Programmable Logic Devices (CPLDs) to perform the aforementioned methods. Fig. 5 is a schematic structural diagram of an apparatus for predicting the pathogenicity of an germline site variation according to an embodiment of the present invention. In this embodiment, the apparatus 500 for predicting the pathogenicity of germline locus variation includes a training data set generating module 501 and a prediction model generating module 502. The training data set generating module 501 is configured to obtain a variation site data set, perform corresponding assignment on each variation site data in the variation site data set according to whether the variation site data is a harmful site, and perform functional annotation on each variation site data based on one or more genetic variation indexes to obtain a training data set. The prediction model generation module 502 is configured to input the training data set into an XGBoost machine learning model, and use a loss function based on a sample balance adjustment parameter to perform model training to obtain a CNN-XGBoost model for predicting pathogenicity of germline locus variation. In some examples of this embodiment, the performing, by the training data set generating module 501, corresponding assignment on each mutation site data in the mutation site data set according to whether the mutation site data is a harmful site includes: assigning pathogenic variant site data and possible pathogenic variant site data in the variant site data set according to harmful sites, and assigning benign variant site data and possible benign variant site data in the variant site data set according to harmless sites. In some examples of this embodiment, the training data set generation module 501 functionally annotates the variant locus data based on one or more genetic variant indicators includes: and functionally annotating the data of each variation site based on the gene mutation frequency value and/or the variation harmfulness prediction value. In some examples of this embodiment, the loss function based on the sample balance adjustment parameter includes: introducing a beta coefficient into a Binary-Logistic regression loss function to perform adaptive adjustment on the classification probability; the loss function after introducing the β coefficient is expressed as:where N denotes the number of samples, yi denotes the ith sample label, p i Representing the probability of the ith sample being classified into the first class; beta is a sample balance adjustment parameter. In some examples of this embodiment, the prediction model generation module 502 performs iterative update calculation on the loss function after the β coefficient is introduced through first order partial derivative calculation and second order partial derivative calculation, and the calculation method is as follows: first order partial derivative calculation: gradient = p i (β-βy i +y i )-y i ； Second-order partial derivative calculation: sesian = (y) i +β-βy i )p i (1-p i )； Wherein, y i Denotes the ith sample tag, p i Representing the probability of the ith sample being classified into the first class; beta is a sample balance adjustment parameter. In some examples of this embodiment, the prediction model generation module 502 performs multiple rounds of adjustment on model parameters of the CNN-XGBoost model for predicting the pathogenicity of germline locus variation based on a grid search method; in each round of adjustment, the parameter values of the optimal result are reserved after the coarse target range traversal is carried out on a plurality of model parameters, then the fine target range is used for the next round of adjustment, and the adjustment process is repeated until the model result is not promoted. It should be noted that: in the germ line locus variation pathogenicity prediction device provided in the above embodiment, only the division of the program modules is exemplified when performing germ line locus variation pathogenicity prediction, and in practical applications, the processing may be distributed to different program modules as needed, that is, the internal structure of the device may be divided into different program modules to complete all or part of the above-described processing. In addition, the device for predicting the pathogenicity of germline locus variation provided by the above embodiment and the method for predicting the pathogenicity of germline locus variation belong to the same concept, and the specific implementation process is described in the method embodiment and will not be described herein again. Those of ordinary skill in the art will understand that: all or part of the steps for implementing the above method embodiments may be performed by hardware associated with a computer program. The aforementioned computer program may be stored in a computer readable storage medium. When executed, the program performs steps comprising the method embodiments described above; and the aforementioned storage medium includes: various media that can store program codes, such as ROM, RAM, magnetic or optical disks. In the embodiments provided herein, the computer-readable and/or writable storage medium may include read-only memory, random-access memory, EEPROM, CD-ROM or other optical disk storage, magnetic disk storage or other magnetic storage devices, flash memory, U-disk, removable hard disk, or any other medium that can be used to store desired program code in the form of instructions or data structures and that can be accessed by a computer. Also, any connection is properly termed a computer-readable medium. For example, if the instructions are transmitted from a website, server, or other remote source using a coaxial cable, fiber optic cable, twisted pair, digital Subscriber Line (DSL), or wireless technologies such as infrared, radio, and microwave, then the coaxial cable, fiber optic cable, twisted pair, DSL, or wireless technologies such as infrared, radio, and microwave are included in the definition of medium. It should be understood, however, that computer-readable-writable storage media and data storage media do not include connections, carrier waves, signals, or other transitory media, but are intended to be non-transitory, tangible storage media. Disk and disc, as used in this application, includes Compact Disc (CD), laser disc, optical disc, digital Versatile Disc (DVD), floppy disk and blu-ray disc where disks usually reproduce data magnetically, while discs reproduce data optically with lasers. In summary, the invention provides a method, a device, a terminal and a medium for predicting the pathogenicity of germline locus variation, and the method comprises the steps of assigning value to variation locus data and carrying out functional annotation to obtain a model training data set, and training by using an optimized unique loss function to obtain a CNN-XGboost model for predicting the pathogenicity of germline locus variation, wherein the classification effect of the model on the training set reaches 99% accuracy, the accuracy in the prediction of a parallel non-intersection test data set reaches 96%, and the over-training bias of the existing method is overcome. The prediction model provided by the invention can assist in interpretation of gene mutation sites which are interpreted as having ambiguous meanings in clinical reports, improve accuracy of interpretation of the mutation sites and assist clinical decisions of doctors. In addition, the pathogenicity of the genetic variation site in the target region can be predicted through a model at the initial stage of product design, the design and optimization of the gene panel are assisted, and the missing detection of the pathogenic site is reduced, so that the product performance is improved. Therefore, the application effectively overcomes various defects in the prior art and has high industrial utilization value. The above embodiments are merely illustrative of the principles and utilities of the present application and are not intended to limit the application. Any person skilled in the art can modify or change the above-described embodiments without departing from the spirit and scope of the present application. Accordingly, it is intended that all equivalent modifications or changes which can be made by those skilled in the art without departing from the spirit and technical concepts disclosed in the present application shall be covered by the claims of the present application.

### Claims

Claims (10) 1. A method for predicting the pathogenicity of an embryonic locus variation, which is characterized by comprising the following steps: obtaining a variation site data set, carrying out corresponding assignment on each variation site data in the variation site data set according to whether the variation site data are harmful sites, and carrying out functional annotation on each variation site data based on one or more gene variation indexes to obtain a training data set; inputting a training data set subjected to dimensionality reduction based on a convolutional neural network into an XGboost machine learning model, and performing model training by using a loss function based on sample balance adjustment parameters to obtain a CNN-XGboost model for predicting the pathogenicity of germline locus variation. 2. The method of predicting the pathogenicity of a germline site variation according to claim 1, wherein assigning a value to each variation site data in the variation site data set based on whether it is a detrimental site comprises: assigning pathogenic variant site data and possible pathogenic variant site data in the variant site data set according to harmful sites, and assigning benign variant site data and possible benign variant site data in the variant site data set according to harmless sites. 3. The method of claim 1, wherein the functionally annotating the data of each mutation site based on one or more genetic mutation indicators comprises: and functionally annotating the data of each variation site based on the gene mutation frequency value and/or the variation harmfulness prediction value. 4. The method of claim 1, wherein the loss function based on the sample balance adjustment parameter comprises: introducing a beta coefficient into a Binary-Logistic regression loss function to carry out adaptive adjustment on the classification probability; the loss function after introducing the β coefficient is expressed as: wherein N represents the number of samples, y i Denotes the ith sample tag, p i Representing the probability of the ith sample being classified into the first class; beta is a sample balance adjustment parameter. 5. The method of claim 4, further comprising iteratively updating the loss function after introducing β coefficients by first and second order partial derivatives calculations, as follows: first order partial derivative calculation: gradient = p i (β-βy i +y i )-y i ； And (3) second-order partial derivative calculation: sesian = (y) i +β-βy i )p i (1-p i )； Wherein, y i Denotes the ith sample tag, p i Representing the probability of the ith sample being classified into the first class; beta is a sample balance adjustment parameter. 6. The method of predicting the pathogenicity of a germline locus variation according to claim 1, further comprising: performing multi-round adjustment on model parameters of the CNN-XGboost model based on a grid search method; in each round of adjustment, the parameter values of the optimal result are reserved after the coarse target range traversal is carried out on a plurality of model parameters, then the fine target range is used for the next round of adjustment, and the adjustment process is repeated until the model result is not promoted. 7. The method for predicting the pathogenicity of germline locus variation according to claim 1, wherein the structure of the CNN-XGboost model comprises a convolutional layer and a full junction layer; connecting the input data with one or more full connection layers after the input data is calculated by the convolution layer; the convolutional layers are represented as follows:wherein C represents a convolutional layer; l is used for the indicator layer; p and q are used as indexes of a current layer and a next layer; i, j denotes the row and column indices; σ denotes the activation method; x represents a datum; θ represents a convolution kernel; b represents a deviation; (u, v) represents the dimensionality of the convolution kernel; the full connection layer converts the characteristics of the data input into the full connection layer through an activation function and a normalization function and then uses the converted data as the input data of the classifier; wherein the activation function comprises a ReLU activation function and the normalization function comprises a Softmax function. 8. An apparatus for predicting the pathogenicity of an embryonal locus variation, comprising: a training data set generation module, configured to obtain a mutation site data set, perform corresponding assignment on each mutation site data in the mutation site data set according to whether the mutation site data is a harmful site, and perform functional annotation on each mutation site data based on one or more genetic mutation indexes to obtain a training data set; and the prediction model generation module is used for inputting the training data set subjected to dimensionality reduction based on the convolutional neural network into the XGboost machine learning model, and performing model training by using a loss function based on sample balance adjustment parameters to obtain a CNN-XGboost model for predicting the pathogenicity of embryonic system locus variation. 9. A computer-readable storage medium having stored thereon a computer program which, when executed by a processor, implements the method for predicting the pathogenicity of a germline locus variant according to any one of claims 1 to 7. 10. An electronic terminal, comprising: a processor and a memory; the memory is used for storing a computer program; the processor is used for executing the computer program stored in the memory to enable the terminal to execute the method for predicting the pathogenicity of the germline locus variation according to any one of claims 1 to 7.
